In our study, we have highlighted the roles of CHKB-AS1 and MAP4 in modulating the PI3K/Akt/mTOR pathway and contributing to NVP-BEZ235 resistance in renal carcinoma. This evidence concerns the gene AKT1 and renal carcinoma.